Stalevo: Levodopa, carbidopa & entacapone (Catechols), intended as improved therapy for Parkinson Disease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9831783 |
| SCHEMBL ID | 3808214 |
| MeSH ID | M0460136 |
| Synonym |
|---|
| stalevo |
| stalevo 150 |
| stalevo 125 |
| stalevo 200 |
| carbidopa/levodopa/entacapone |
| 745835-09-0 |
| carbidopa, levodopa, and entacapone |
| elc200 |
| l-tyrosine, 3-hydroxy-, mixt. with (2e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide and (alphas)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid |
| stalevo 100 |
| stalevo 75 |
| stalevo 50 |
| DTXSID10225560 |
| SCHEMBL3808214 |
Stalevo is a new levodopa product that combines carbidopa, levodOPA and entacapone in one tablet.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Stalevo is a new levodopa product that combines carbidopa, levodopa and entacapone in one tablet." | ( An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D, 2005) | 1.29 |
Stalevo treatment resulted in significant improvements in PDQ-39 and UPDRS (II + III) scores. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Stalevo treatment resulted in significant improvements in PDQ-39 and UPDRS (II + III) scores (p < 0.001)." | ( An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D, 2005) | 1.29 |
| "Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess/Comtan)." | ( Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional Agid, Y; Brooks, DJ; Eggert, K; Holopainen, A; Ostergaard, K; Widner, H, 2005) | 0.91 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Assessments included tolerability measures, adverse events profile, the disease-specific quality of life instrument PDQ-39, UPDRS parts II, III, and question 39 and investigator and patient global clinical assessments." | ( An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D, 2005) | 0.57 |
| "14 subjects (8%) discontinued treatment with Stalevo, of which 12 (7%) were due to adverse events." | ( An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D, 2005) | 0.83 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, due to the short duration of action of conventional levodopa/decarboxylase inhibitor formulations, multiple dosing may be required in individual patients with persisting symptoms." | ( Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. Ellmén, J; Hirvonen, K; Karvinen, J; Polo, O; Vahteristo, M; Ylä-Sahra, R, ) | 0.13 |
| " Thus, a reduction of the total levodopa dosage would be recommended." | ( Should levodopa dose be reduced when switched to stalevo? Hernández, B; Kulisevsky, J; Linazasoro, G, 2008) | 0.6 |
| " The results of the study revealed that the drug substantially reduced motor deficit, increased the "on"-period, decreased the duration and severity of the "off" period, improved the daily activity and quality of life of patients compared to standard therapy with an additional dosage of levodopa/DDC inhibitor." | ( [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations]. Chigir', IP; Dokadina, LV; Fedorova, NV; Levin, OS; Makhnev, SO; Smolentseva, IG, 2008) | 0.6 |
| "In this open-label naturalistic study, 75 PD patients (group A) completely switched standard LD (Sinemet or Madopar) with Sirio at an equivalent dosage (800-1000 mg/d)." | ( Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. Antonini, A; Guidi, M; Mancini, F; Martignoni, E; Pacchetti, C; Sciarretta, M; Stocchi, F; Zangaglia, R, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (57.69) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (76.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 17 (58.62%) | 5.53% |
| Reviews | 2 (6.90%) | 6.00% |
| Case Studies | 3 (10.34%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (24.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||